Skip to main content
Erschienen in: Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 1/2022

14.01.2022 | Koronare Herzerkrankung | CME

Update Koronarchirurgie 2022: Terminologie und Indikation

verfasst von: Prof. Dr. Ardawan J. Rastan, Tamer Ghazy, Heidi Niehaus

Erschienen in: Zeitschrift für Herz-,Thorax- und Gefäßchirurgie | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Über die Jahrzehnte haben sich Indikationsstellung, Verwendung der Bypass-Gefäße, operative Verfahren, perioperatives Management und postoperative Medikation in der Koronarchirurgie kontinuierlich gewandelt. Die Kenntnis der wissenschaftlichen Daten und die klinische Erfahrung erlauben es dem Koronarchirurgen, sehr fundierte und trotzdem individualisierte Therapieentscheidungen zu treffen und in Herz-Team-Besprechungen zum Nutzen der Patienten zu vertreten. Die operative Myokardrevaskularisation bei operablen Patienten mit prognostisch relevanter koronarer Dreigefäßerkrankung und/oder Hauptstammstenose bleibt die Therapieoption der ersten Wahl, umso mehr bei komplexer Morphologie der koronaren Herzerkrankung und Diabetes mellitus. Der vorliegende CME-Beitrag vermittelt aktuelle Entwicklungen in der Koronarchirurgie und geht, basierend auf aktuellen Leitlinien und klinischen Studienergebnissen, auf die Terminologie und die Indikationsstellung zur operativen Myokardrevaskularisation ein.
Literatur
1.
Zurück zum Zitat Leitz KH (2009) Entstehung der herzchirurgischen Kliniken in Deutschland. Z Herz- Thorax- Gefäßchir 23:27–32CrossRef Leitz KH (2009) Entstehung der herzchirurgischen Kliniken in Deutschland. Z Herz- Thorax- Gefäßchir 23:27–32CrossRef
2.
Zurück zum Zitat Knuuti J, Wijns W et al (2019) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407–477CrossRef Knuuti J, Wijns W et al (2019) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407–477CrossRef
3.
Zurück zum Zitat Tonino PA, De Bruyne B, Pijls NH et al (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360:213–224CrossRefPubMed Tonino PA, De Bruyne B, Pijls NH et al (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360:213–224CrossRefPubMed
4.
Zurück zum Zitat van Nunen LX, Zimmermann FM, Tonino PA et al (2015) Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5‑year follow-up of a randomised controlled trial. Lancet 386:1853–1860CrossRefPubMed van Nunen LX, Zimmermann FM, Tonino PA et al (2015) Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5‑year follow-up of a randomised controlled trial. Lancet 386:1853–1860CrossRefPubMed
5.
Zurück zum Zitat De Bruyne B, Pijls NH, Kalesan B et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991–1001CrossRefPubMed De Bruyne B, Pijls NH, Kalesan B et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991–1001CrossRefPubMed
6.
Zurück zum Zitat Xaplanteris P, Fournier S, Pijls NHJ et al (2018) Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med 379:250–259CrossRefPubMed Xaplanteris P, Fournier S, Pijls NHJ et al (2018) Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med 379:250–259CrossRefPubMed
7.
Zurück zum Zitat Toth GG, DeBruyne B, Kala P et al (2019) Graft patency after FFR-guided versus angiography-guided coronary artery bypass grafting: the Graffiti trial. EuroIntervention 15:e999–e1005CrossRefPubMed Toth GG, DeBruyne B, Kala P et al (2019) Graft patency after FFR-guided versus angiography-guided coronary artery bypass grafting: the Graffiti trial. EuroIntervention 15:e999–e1005CrossRefPubMed
8.
Zurück zum Zitat Timbadia D, Ler A, Sazzad F et al (2020) FFR-guided versus coronary angiogram-guided CABG: a review and meta-analysis of prospective randomized controlled trials. Card Surg 35:2785–2793CrossRef Timbadia D, Ler A, Sazzad F et al (2020) FFR-guided versus coronary angiogram-guided CABG: a review and meta-analysis of prospective randomized controlled trials. Card Surg 35:2785–2793CrossRef
10.
Zurück zum Zitat Yusuf S, Zucker D, Peduzzi P et al (1994) Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344:563–570CrossRefPubMed Yusuf S, Zucker D, Peduzzi P et al (1994) Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344:563–570CrossRefPubMed
11.
Zurück zum Zitat Frye RL, August P, Brooks MM et al (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360:2503–2515CrossRefPubMed Frye RL, August P, Brooks MM et al (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360:2503–2515CrossRefPubMed
12.
Zurück zum Zitat Nishigaki K, Yamazaki T, Kitabatake A et al (2008) Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Inter 1:469–479 (Japanese Stable Angina Pectoris Study Investigators)CrossRef Nishigaki K, Yamazaki T, Kitabatake A et al (2008) Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Inter 1:469–479 (Japanese Stable Angina Pectoris Study Investigators)CrossRef
13.
Zurück zum Zitat Boden WE, O’Rourke RA, Teo KK et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503–1516CrossRefPubMed Boden WE, O’Rourke RA, Teo KK et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503–1516CrossRefPubMed
14.
Zurück zum Zitat Al-Lamee R, Thompson D, Dehbi HM et al (2018) Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 391:31–40CrossRefPubMed Al-Lamee R, Thompson D, Dehbi HM et al (2018) Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 391:31–40CrossRefPubMed
15.
Zurück zum Zitat Maron DJ, Hochman JS, Reynolds HR et al (2020) Initial invasive or conservative strategy for stable coronary disease. N Eng J Med 382:1395–1407CrossRef Maron DJ, Hochman JS, Reynolds HR et al (2020) Initial invasive or conservative strategy for stable coronary disease. N Eng J Med 382:1395–1407CrossRef
16.
Zurück zum Zitat Navarese EP, Lansky AJ, Kereiakes DJ et al (2021) Cardiac mortality in patients randomized to elective coronary revascularization. Eur Heart J 42:4638–4651CrossRefPubMed Navarese EP, Lansky AJ, Kereiakes DJ et al (2021) Cardiac mortality in patients randomized to elective coronary revascularization. Eur Heart J 42:4638–4651CrossRefPubMed
17.
Zurück zum Zitat Lawton JS, Tamis-Holland JE, Bangalore S et al (2021) 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. https://doi.org/10.1161/CIR.0000000000001039 Lawton JS, Tamis-Holland JE, Bangalore S et al (2021) 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. https://​doi.​org/​10.​1161/​CIR.​0000000000001039​
18.
19.
Zurück zum Zitat Sousa-Uva M, Neumann FJ, Ahlsson A et al (2019) 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 55:4–90CrossRefPubMed Sousa-Uva M, Neumann FJ, Ahlsson A et al (2019) 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 55:4–90CrossRefPubMed
20.
Zurück zum Zitat Kapur A, Hall RJ, Malik IS et al (2010) Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1‑year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 55:432–440CrossRef Kapur A, Hall RJ, Malik IS et al (2010) Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1‑year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 55:432–440CrossRef
21.
Zurück zum Zitat Serruys PW, Maurice MC, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. N Engl J Med 360:961–972CrossRef Serruys PW, Maurice MC, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. N Engl J Med 360:961–972CrossRef
22.
Zurück zum Zitat Thuijs DJFM, Kappetein AP, Serruys PW et al (2019) Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 394:1325–1334CrossRef Thuijs DJFM, Kappetein AP, Serruys PW et al (2019) Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 394:1325–1334CrossRef
23.
Zurück zum Zitat Park SJ, Ahn JM, Kim YH et al (2015) Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 372:1204–1212CrossRef Park SJ, Ahn JM, Kim YH et al (2015) Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 372:1204–1212CrossRef
25.
Zurück zum Zitat Esper RB, Farkouh ME, Ribeiro EE et al (2018) SYNTAX score in patients with diabetes undergoing coronary revascularization in the FREEDOM trial. J Am Coll Cardiol 72:2826–2837CrossRef Esper RB, Farkouh ME, Ribeiro EE et al (2018) SYNTAX score in patients with diabetes undergoing coronary revascularization in the FREEDOM trial. J Am Coll Cardiol 72:2826–2837CrossRef
26.
Zurück zum Zitat Farkouh ME, Domanski M, Dangas GD et al (2019) Long-term survival following multivessel revascularization in patients with diabetes. The FREEDOM follow-on study. J Am Coll Cardiol 73:629–638CrossRef Farkouh ME, Domanski M, Dangas GD et al (2019) Long-term survival following multivessel revascularization in patients with diabetes. The FREEDOM follow-on study. J Am Coll Cardiol 73:629–638CrossRef
27.
Zurück zum Zitat Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384CrossRefPubMed Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384CrossRefPubMed
28.
Zurück zum Zitat Kamalesh M, Sharp TG, Tang XC et al (2013) Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol 61:808–816CrossRefPubMed Kamalesh M, Sharp TG, Tang XC et al (2013) Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol 61:808–816CrossRefPubMed
29.
Zurück zum Zitat Jeong YJ, Ahn JM, Hyun J et al (2021) Ten-year outcomes after drug-eluting stents or bypass surgery for left main coronary disease in patients with and without diabetes mellitus: the PRECOMBAT extended follow-up study. J Am Heart Assoc 10:e19834CrossRefPubMed Jeong YJ, Ahn JM, Hyun J et al (2021) Ten-year outcomes after drug-eluting stents or bypass surgery for left main coronary disease in patients with and without diabetes mellitus: the PRECOMBAT extended follow-up study. J Am Heart Assoc 10:e19834CrossRefPubMed
30.
Zurück zum Zitat Buszman PE, Buszman PP, Banasiewicz-Szkróbka I et al (2016) Left main stenting in comparison with surgical revascularization: 10-year outcomes of the (left main coronary artery stenting) LE MANS trial. JACC Cardiovasc Interv 22:318–327CrossRef Buszman PE, Buszman PP, Banasiewicz-Szkróbka I et al (2016) Left main stenting in comparison with surgical revascularization: 10-year outcomes of the (left main coronary artery stenting) LE MANS trial. JACC Cardiovasc Interv 22:318–327CrossRef
31.
Zurück zum Zitat Buszman PE, Kiesz SR, Bochenek A et al (2008) Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol 51:538–545CrossRefPubMed Buszman PE, Kiesz SR, Bochenek A et al (2008) Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol 51:538–545CrossRefPubMed
32.
Zurück zum Zitat Boudriot E, Thiele H, Walther T et al (2011) Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol 57:538–545CrossRefPubMed Boudriot E, Thiele H, Walther T et al (2011) Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol 57:538–545CrossRefPubMed
33.
Zurück zum Zitat Stone GW, Kappetein AP, Sabik JF et al (2019) Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med 381:1820–1830CrossRefPubMed Stone GW, Kappetein AP, Sabik JF et al (2019) Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med 381:1820–1830CrossRefPubMed
34.
Zurück zum Zitat Stone GW, Sabik JF, Serruys PW et al (2016) Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 375:2223–2235CrossRefPubMed Stone GW, Sabik JF, Serruys PW et al (2016) Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 375:2223–2235CrossRefPubMed
35.
Zurück zum Zitat Holm NR, Mäkikallio T, Lindsay MM et al (2020) Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5‑year outcomes from the randomised, non-inferiority NOBLE trial. Lancet 395:191–199CrossRefPubMed Holm NR, Mäkikallio T, Lindsay MM et al (2020) Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5‑year outcomes from the randomised, non-inferiority NOBLE trial. Lancet 395:191–199CrossRefPubMed
36.
Zurück zum Zitat Mäkikallio T, Holm NR, Lindsay M et al (2016) Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet 388:2743–2752CrossRef Mäkikallio T, Holm NR, Lindsay M et al (2016) Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet 388:2743–2752CrossRef
Metadaten
Titel
Update Koronarchirurgie 2022: Terminologie und Indikation
verfasst von
Prof. Dr. Ardawan J. Rastan
Tamer Ghazy
Heidi Niehaus
Publikationsdatum
14.01.2022
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Herz-,Thorax- und Gefäßchirurgie / Ausgabe 1/2022
Print ISSN: 0930-9225
Elektronische ISSN: 1435-1277
DOI
https://doi.org/10.1007/s00398-021-00488-1

Weitere Artikel der Ausgabe 1/2022

Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 1/2022 Zur Ausgabe

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.